Pliant Therapeutics, Inc. Overview
Pro stress-test →Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel integrin-based therapies for fibrotic diseases and solid tumors. The company leverages its expertise in integrin biology and TGF-β modulation to address serious conditions including idiopathic pulmonary fibrosis, primary sclerosing cholangitis, and liver fibrosis associated with NASH.
Strategic Profile
Pro stress-test →Pliant pivoted away from its lead IPF program (bexotegrast) following disappointing Phase 2b trial results in March 2025, redirecting focus toward its oncology program with PLN-101095 showing promising antitumor activity. The company maintains a portfolio approach with multiple clinical-stage programs targeting different integrin pathways and therapeutic areas, demonstrating scientific depth in integrin modulation.
Competitive Landscape
Pro stress-test →Pliant competes in antifibrotic therapeutics against companies like Boehringer Ingelheim, Roche (Galapagos assets), and FibroGen, while the oncology pivot positions it against immuno-oncology specialists. The company differentiates through its integrin-focused platform approach, though the failure of bexotegrast dilutes confidence in the fibrotic disease strategy and forces reliance on early-stage oncology success.
Industry Context
Pliant Therapeutics, Inc. operates in Clinical-Stage Biopharmaceuticals / Specialty Therapeutics.
Key facts
Founded: 2015 · Headquarters: South San Francisco, California · Market cap: $71M